Disruptive Pharma AB (publ) (STO:DPHA)
Sweden · Delayed Price · Currency is SEK 1.060
-0.076 (-6.69%)
At close: Oct 9, 2026
Disruptive Pharma AB Earnings Call Transcripts
Fiscal Year 2025
-
The POINTER phase 2B study of RMC-035 in heart surgery patients did not meet its primary or secondary endpoints, showing no significant benefit over placebo and contrasting with prior AKITA results. Strategic review and full data analysis are ongoing, with likely discontinuation of RMC-035 in this indication.